Glomerular type 1 angiotensin receptors augment kidney injury and inflammation in murine autoimmune nephritis

Journal of Clinical Investigation

Volumn 119, Issue 4, 2009, Pages 943-953

  Crowley, Steven D ^a   Vasievich, Matthew P ^a   Ruiz, Phillip ^b   Gould, Samantha K ^a   Parsons, Kelly K ^a   Kathy Pazmino, A ^a   Facemire, Carie ^a   Chen, Benny J ^a   Kim, Hyung Suk ^c   Tran, Trinh T ^a   Pisetsky, David S ^a   Barisoni, Laura ^d   Prieto Carrasquero, Minolfa C ^e   Jeansson, Marie ^f   Foster, Mary H ^a   Coffman, Thomas M ^a,g  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^f MOUNT SINAI HOSPITAL   (Canada)

^g DURHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1A RECEPTOR; ANGIOTENSIN 1B RECEPTOR; BIOLOGICAL MARKER; CYTOKINE; HYDRALAZINE; LOSARTAN; MESSENGER RNA; RENIN; CHEMOKINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GLOMERULONEPHRITIS; HEART; HYPERTENSION; HYPOTENSION; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; JOINT; KIDNEY DISEASE; KIDNEY INJURY; KIDNEY PARENCHYMA; MALE; MOUSE; MURPHY ROTHS LARGE LYMPHOPROLIFERATIVE MOUSE; NEPHRITIS; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN VARIANT; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SKIN; SURVIVAL; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; GENETICS; IMMUNOLOGY; INJURY; KIDNEY; METABOLISM; MOUSE MUTANT; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; AUTOIMMUNE DISEASES; CHEMOKINES; CYTOKINES; FEMALE; KIDNEY; MALE; MICE; MICE, INBRED MRL LPR; MICE, KNOCKOUT; NEPHRITIS; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN-ANGIOTENSIN SYSTEM; RNA, MESSENGER;

EID: 65249105407     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI34862     Document Type: Article

References (74)

1. Ito, M., et al. 1995. Regulation of blood pressure by the type 1A angiotensin II receptor gene. Proc. Natl. Acad. Sci. U. S. A. 92:3521-3525.
2. Hilgers, K.F., and Mann, J.F. 2002. ACE inhibitors versus AT(1) receptor antagonists in patients with chronic renal disease. J. Am. Soc. Nephrol. 13:1100-1108.
3. Gray, M.O., Long, C.S., Kalinyak, J.E., Li, H.T., and Karliner, J.S. 1998. Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-beta 1 and endothelin-1 from fibroblasts. Cardiovasc. Res. 40:352-363.
4. Furukawa, Y., Matsumori, A., Hirozane, T., and Sasayama, S. 1996. Angiotensin II receptor antagonist TCV-116 reduces graft coronary artery disease and preserves graft status in a murine model. A comparative study with captopril. Circulation. 93:333-339.
5. Nataraj, C., et al. 1999. Angiotensin II regulates cellular immune responses through a calcineurindependent pathway. J. Clin. Invest. 104:1693-1701.
6. Nishida, M., et al. 2002. Absence of angiotensin II type 1 receptor in bone marrow-derived cells is detrimental in the evolution of renal fibrosis. J. Clin. Invest. 110:1859-1868.
7. Wolf, G., et al. 1997. Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells. Role of the angiotensin type 2 receptor. J. Clin. Invest. 100:1047-1058.
8. Andrews, B.S., et al. 1978. Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J. Exp. Med. 148:1198-1215.
9. Theofilopoulos, A.N., and Dixon, F.J. 1981. Etiopathogenesis of murine SLE. Immunol. Rev. 55:179-216.
10. De Albuquerque, D.A., et al. 2004. An ACE inhibitor reduces Th2 cytokines and TGF-beta1 and TGF-beta2 isoforms in murine lupus nephritis. Kidney Int. 65:846-859.
11. Perez De Lema, G., et al. 2003. Angiotensin inhibition reduces glomerular damage and renal chemokine expression in MRL/lpr mice. J. Pharmacol. Exp. Ther. 307:275-281.
12. Prkacin, I., Novak, B., Sertic, J., and Mrzljak, A. 2001. Angiotensin-converting enzyme gene polymorphism in patients with systemic lupus. Acta Med. Croatica. 55:73-76.
13. Sato, H., et al. 1998. Association of an insertion polymorphism of angiotensin-converting enzyme gene with the activity of systemic lupus erythematosus. Lupus. 7:530-534.
14. Kaufman, K.M., et al. 2001. Linkage analysis of angiotensin-converting enzyme (ACE) insertion/ deletion polymorphism and systemic lupus erythematosus. Mol. Cell. Endocrinol. 177:81-85.
15. Herlitz, H., Edeno, C., Mulec, H., Westberg, G., and Aurell, M. 1984. Captopril treatment of hypertension and renal failure in systemic lupus erythematosus. Nephron. 38:253-256.
16. Spurney, R.F., Ruiz, P., Pisetsky, D.S., and Coffman, T.M. 1991. Enhanced renal leukotriene production in murine lupus: role of lipoxygenase metabolites. Kidney Int. 39:95-102.
17. Crowley, S.D., et al. 2008. Stimulation of lymphocyte responses by angiotensin II promotes kidney injury in hypertension. Am. J. Physiol. Renal Physiol. 295:F515-F524.
18. Chan, R.W., et al. 2004. Expression of chemokine and fibrosing factor messenger RNA in the urinary sediment of patients with lupus nephritis. Arthritis Rheum. 50:2882-2890.
19. Wolf, G. 1998. Link between angiotensin II and TGF-beta in the kidney. Miner. Electrolyte Metab. 24:174-180.
20. Kagami, S., Border, W.A., Miller, D.E., and Noble, N.A. 1994. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J. Clin. Invest. 93:2431-2437.
21. Weinberg, J.B., et al. 1994. The role of nitric oxide in the pathogenesis of spontaneous murine autoimmune disease: increased nitric oxide production and nitric oxide synthase expression in MRL-lpr/ lpr mice, and reduction of spontaneous glomerulonephritis and arthritis by orally administered NGmonomethyl-L-arginine. J. Exp. Med. 179:651-660.
22. Theofilopoulos, A., et al. 1985. Association of lpr gene with graft-vs.-host disease-like syndrome. J. Exp. Med. 162:1-18.
23. Allen, R.D., Marshall, J.D., Roths, J.B., and Sidman, C.L. 1990. Bone marrow transplantation from mutant lpr/lpr mice. Functional abnormalities rather than alloantigenic differences appear to determine the development of a graft-vs.-host-like syndrome. Eur. J. Immunol. 20:2057-2066.
24. Sugaya, T., et al. 1995. Angiotensin II type 1a receptor-deficient mice with hypotension and hyperreninemia. J. Biol. Chem. 270:18719- 18722.
25. Oliverio, M.I., et al. 1998. Renal growth and development in mice lacking AT1A receptors for angiotensin II. Am. J. Physiol. 274:F43-F50.
26. Cervenka, L., Mitchell, K.D., Oliverio, M.I., Coffman, T.M., and Navar, L.G. 1999. Renal function in the AT1A receptor knockout mouse during normal and volume-expanded conditions. Kidney Int. 56:1855-1862.
27. Prieto-Carrasquero, M.C., et al. 2004. Enhancement of collecting duct renin in angiotensin II-dependent hypertensive rats. Hypertension. 44:223-229.
28. Oliverio, M.I., Best, C.F., Smithies, O., and Coffman, T.M. 2000. Regulation of sodium balance and blood pressure by the AT(1A) receptor for angiotensin II. Hypertension. 35:550-554.
29. Crowley, S.D., et al. 2005. Distinct roles for the kidney and systemic tissues in blood pressure regulation by the renin-angiotensin system. J. Clin. Invest. 115:1092-1099.
30. Harrison-Bernard, L.M., Cook, A.K., Oliverio, M.I., and Coffman, T.M. 2003. Renal segmental microvascular responses to ANG II in AT1A receptor null mice. Am. J. Physiol. Renal Physiol. 284:F538-F545.
31. Bouby, N., et al. 1997. Expression of type 1 angiotensin II receptor subtypes and angiotensin IIinduced calcium mobilization along the rat nephron. J. Am. Soc. Nephrol. 8:1658-1667.
32. Harrison-Bernard, L.M., Monjure, C.J., and Bivona, B.J. 2006. Efferent arterioles exclusively express the subtype 1A angiotensin receptor: functional insights from genetic mouse models. Am. J. Physiol. Renal Physiol. 290:F1177-F1186.
33. Barisoni, L., Bruggeman, L.A., Mundel, P., D'Agati, V.D., and Klotman, P.E. 2000. HIV-1 induces renal epithelial dedifferentiation in a transgenic model of HIV-associated nephropathy. Kidney Int. 58:173-181.
34. Barisoni, L., Madaio, M.P., Eraso, M., Gasser, D.L., and Nelson, P.J. 2005. The kd/kd mouse is a model of collapsing glomerulopathy. J. Am. Soc. Nephrol. 16:2847-2851.
35. Dahlof, B., et al. 2002. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 359:995-1003.
36. [No authors listed]. 1987. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N. Engl. J. Med. 316:1429-1435.
37. Brenner, B.M., et al. 2001. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345:861-869.
38. Crowley, S.D., et al. 2006. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc. Natl. Acad. Sci. U. S. A. 103:17985-17990.
39. Ruiz-Ortega, M., et al. 1998. Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-kappa B activation and monocyte chemoattractant protein-1 synthesis. J. Immunol. 161:430-439.
40. Muller, D.N., et al. 2002. Immunosuppressive treatment protects against angiotensin II-induced renal damage. Am. J. Pathol. 161:1679-1693.
41. Guzik, T.J., et al. 2007. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J. Exp. Med. 204:2449-2460.
42. Amuchastegui, S.C., et al. 1998. Chronic allograft nephropathy in the rat is improved by angiotensin II receptor blockade but not by calcium channel antagonism. J. Am. Soc. Nephrol. 9:1948-1955.
43. Herlitz, H., Tarkowski, A., Svalander, C., Volkmann, R., and Westberg, G. 1988. Beneficial effect of captopril on systemic lupus erythematosus-like disease in MRL lpr/lpr mice. Int. Arch. Allergy Appl. Immunol. 85:272-277.
44. Crowley, S.D., Tharaux, P.L., Audoly, L.P., and Coffman, T.M. 2004. Exploring type I angiotensin (AT1) receptor functions through gene targeting. Acta Physiol. Scand. 181:561-570.
45. Blantz, R.C., Konnen, K.S., and Tucker, B.J. 1976. Angiotensin II effects upon the glomerular microcirculation and ultrafiltration coefficient of the rat. J. Clin. Invest. 57:419-434.
46. Zatz, R., et al. 1986. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J. Clin. Invest. 77:1925-1930.
47. Anderson, S., Meyer, T.W., Rennke, H.G., and Brenner, B.M. 1985. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J. Clin. Invest. 76:612-619.
48. Kim, J.M., et al. 2003. CD2-associated protein haploinsufficiency is linked to glomerular disease susceptibility. Science. 300:1298-1300.
49. Kaplan, J.M., et al. 2000. Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis. Nat. Genet. 24:251-256.
50. Winn, M.P., et al. 2005. A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science. 308:1801-1804.
51. Macconi, D., et al. 2000. Effect of angiotensinconverting enzyme inhibition on glomerular basement membrane permeability and distribution of zonula occludens-1 in MWF rats. J. Am. Soc. Nephrol. 11:477-489.
52. Mifsud, S.A., et al. 2001. Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade. Diabetologia. 44:878-882.
53. Sharma, M., Sharma, R., Greene, A.S., McCarthy, E.T., and Savin, V.J. 1998. Documentation of angiotensin II receptors in glomerular epithelial cells. Am. J. Physiol. 274:F623-F627.
54. Durvasula, R.V., et al. 2004. Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int. 65:30-39.
55. Masutani, K., et al. 2001. Predominance of Th1 immune response in diffuse proliferative lupus nephritis. Arthritis Rheum. 44:2097-2106.
56. Peng, S.L., Moslehi, J., and Craft, J. 1997. Roles of interferon-gamma and interleukin-4 in murine lupus. J. Clin. Invest. 99:1936-1946.
57. Takahashi, S., et al. 1996. Imbalance towards Th1 predominance is associated with acceleration of lupus-like autoimmune syndrome in MRL mice. J. Clin. Invest. 97:1597-1604.
58. Balomenos, D., Rumold, R., and Theofilopoulos, A.N. 1998. Interferon-gamma is Required for Lupus-like Disease and Lymphoaccumulation in MRL-lpr Mice. J. Clin. Invest. 101:364-371.
59. Haas, C., Ryffel, B., and Le Hir, M. 1997. IFNgamma is essential for the development of autoimmune glomerulonephritis in MRL/Ipr mice. J. Immunol. 158:5484-5491.
60. Carvalho-Pinto, C.E., et al. 2002. Autocrine production of IFN-gamma by macrophages controls their recruitment to kidney and the development of glomerulonephritis in MRL/lpr mice. J. Immunol. 169:1058-1067.
61. Border, W.A., and Noble, N.A. 1998. Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis. Hypertension. 31:181-188.
62. MacKay, K., et al. 1989. Transforming growth factor-beta. Murine glomerular receptors and responses of isolated glomerular cells. J. Clin. Invest. 83:1160-1167.
63. Sun, Y., Zhang, J., Zhang, J.Q., and Ramires, F.J. 2000. Local angiotensin II and transforming growth factor-beta1 in renal fibrosis of rats. Hypertension. 35:1078-1084.
64. Goulet, J.L., et al. 1999. Deficiency of 5-lipoxygenase abolishes sex-related survival differences in MRL-lpr/lpr mice. J. Immunol. 163:359-366.
65. Hylkema, M.N., et al. 1994. Clinical evaluation of a modified ELISA, using photobiotinylated DNA, for the detection of anti-DNA antibodies. J. Immunol. Methods. 170:93-102.
66. Ito, M.R., Ono, M., Itoh, J., and Nose, M. 2003. Bone marrow cell transfer of autoimmune diseases in a MRL strain of mice with a deficit in functional Fas ligand: dissociation of arteritis from glomerulonephritis. Pathol. Int. 53:518-524.
67. Chen, B.J., Cui, X., Sempowski, G.D., Domen, J., and Chao, N.J. 2004. Hematopoietic stem cell dose correlates with the speed of immune reconstitution after stem cell transplantation. Blood. 103:4344-4352.
68. Mickisch, G., et al. 1992. Transplantation of bone marrow cells from transgenic mice expressing the human MDR1 gene results in long-term protection against the myelosuppressive effect of chemotherapy in mice. Blood. 79:1087-1093.
69. Thomas, D.W., et al. 2003. Proinflammatory actions of thromboxane receptors to enhance cellular immune responses. J. Immunol. 171:6389-6395.
70. Spurney, R.F., et al. 1994. Leukotrienes in renal transplant rejection in rats. Distinct roles for leukotriene B4 and peptidoleukotrienes in the pathogenesis of allograft injury. J. Immunol. 152:867-876.
71. Kim, H.S., Lee, G., John, S.W., Maeda, N., and Smithies, O. 2002. Molecular phenotyping for analyzing subtle genetic effects in mice: application to an angiotensinogen gene titration. Proc. Natl. Acad. Sci. U. S. A. 99:4602-4607.
72. Cui, S., Li, C., Ema, M., Weinstein, J., and Quaggin, S.E. 2005. Rapid isolation of glomeruli coupled with gene expression profiling identifies downstream targets in Pod1 knockout mice. J. Am. Soc. Nephrol. 16:3247-3255.
73. Eremina, V., et al. 2006. Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival. J. Am. Soc. Nephrol. 17:724-735.
74. MacKay, K., et al. 1988. Glomerular epithelial, mesangial, and endothelial cell lines from transgenic mice. Kidney Int. 33:677-684.